Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
levels decreased » levels increased (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
levels decreased » levels increased (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
-
2901
-
2902
-
2903
-
2904
-
2905
-
2906
Summary of post-treatment disease course measures from MDMA-AT publications.
Published 2025Subjects: -
2907
Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.
Published 2025Subjects: -
2908
-
2909
-
2910
Summary of post-treatment disease course measures from off-label medications clinical trials.
Published 2025Subjects: -
2911
Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.
Published 2025Subjects: -
2912
Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.
Published 2025Subjects: -
2913
Summary of post-treatment disease course measures from clinical trials with psychotherapies.
Published 2025Subjects: -
2914
-
2915
Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.
Published 2025Subjects: -
2916
Recruitment flow diagram of the current study.
Published 2025“…Phase 1 EQ-VAS decreases were associated with female sex, lower somatic symptom, fewer comorbidities, lack of expectation for a fast recovery, higher ISS, higher injury pain, neck, spine/back or lower extremity injuries. …”
-
2917
-
2918
-
2919
-
2920